Durgical
EN
Open the app

Tumour growth kinetics and the behaviour of cancer cells

How fast tumours grow, why they are found late, and which normal growth brakes cancer cells lose.

Updated

Key facts

  • Doubling time, the time a tumour takes to double in size, ranges from days (some lymphomas and childhood tumours) to months or years (many carcinomas).
  • About 30 doublings turn one cell into a tumour of about 1 cm (around 10⁹ cells), the size at which it is usually found; only about 10 more doublings reach a lethal mass.
  • Growth is Gompertzian: fast while small, then slower as the tumour outgrows its blood supply and loses more cells.
  • Normal cells stop dividing when they touch each other (contact inhibition) and need to be attached to divide (anchorage dependence); cancer cells lose both, pile up in layers and grow even in soft agar.
  • Chemotherapy kills a constant fraction of cells with each cycle (log kill), and dividing cells are the most sensitive.

Small or large tumour?

FeatureSmall (early or left after surgery)Large (bulky, late)
Growth fractionHigh: most cells are dividingLow: many cells resting or dying
Doubling timeShortLonger (Gompertzian slowing)
Blood supply and oxygenGoodPoor centre, hypoxia and necrosis
Sensitivity to chemotherapyHighLower
Resistant clonesFewMore likely to be present already

In detail

  • The growth fraction is the share of tumour cells that are dividing; it is high in small tumours and falls as they grow.
  • Repeated cycles, combinations of drugs and adjuvant treatment after surgery aim at a small tumour burden, when the growth fraction is high and fewer resistant cells exist.
  • Oncofetal antigens are fetal proteins re-expressed by tumours: α-fetoprotein (hepatocellular carcinoma, germ-cell tumours) and carcinoembryonic antigen (colorectal cancer).
  • Tissue polypeptide antigen and related markers (TPS, CYFRA 21-1) are cytokeratin fragments released by proliferating epithelial tumour cells; they reflect proliferation but are not specific for any tumour.
Also called
Doubling time and Gompertzian growth, Contact inhibition and anchorage dependence

Clinical notes

  • Because a tumour has gone through most of its doublings before it can be felt or seen, screening aims to find it earlier.
  • Tumour markers are best used to follow treatment and recurrence, not to screen healthy people.

Common traps

  • A tumour found at 1 cm has only just started: it has already gone through about 30 of the roughly 40 doublings to a lethal size, often years of silent growth.
  • Each chemotherapy cycle removes a fixed number of cells: it removes a fixed fraction (log kill), so killing 99 % of 10¹¹ cells still leaves 10⁹, a tumour of detectable size.
  • Large tumours grow fastest because they have the most cells: their growth fraction is lower and their doubling time longer; small tumours grow proportionally faster.
  • A raised tumour marker in a healthy person means cancer: markers lack the sensitivity and specificity for screening; they are mainly used to follow a known tumour.

Test yourself

Think of the answer, then tap the question to see it.

Why is a 1 cm tumour already «old»?

It has gone through about 30 of the roughly 40 doublings to a lethal size, so most of its life is already behind it.

What does «log kill» mean in chemotherapy?

Each cycle kills a constant fraction of tumour cells, not a constant number, so repeated cycles are needed.

A child with Burkitt lymphoma, which has a very short doubling time, starts chemotherapy and two days later has high potassium, phosphate and uric acid. Why?

A very high growth fraction makes the tumour exquisitely sensitive: huge numbers of cells die at once and release their contents (tumour lysis syndrome).

After a breast cancer is completely removed, chemotherapy is given although no tumour can be seen. Why?

Any micrometastases are small, with a high growth fraction and few resistant cells, so log kill is most likely to eradicate them now.

Add to my cards (4)

Connections

Educational information, not medical advice. For any symptom, see a health professional.

Sources: What Is Cancer? (National Cancer Institute (NCI), 2026); Tumor Markers (National Cancer Institute (NCI), 2026).

← All of biochemistry

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.